Insulet/$PODD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Ticker
$PODD
Sector
Primary listing
Employees
5,400
Headquarters
Website
Insulet Metrics
BasicAdvanced
$16B
66.19
$3.48
1.42
-
Price and volume
Market cap
$16B
Beta
1.42
52-week high
$354.88
52-week low
$216.49
Average daily volume
1.1M
Financial strength
Current ratio
2.814
Quick ratio
1.813
Long term debt to equity
65.681
Total debt to equity
66.176
Interest coverage (TTM)
7.98%
Profitability
EBITDA (TTM)
564.2
Gross margin (TTM)
71.63%
Net profit margin (TTM)
9.12%
Operating margin (TTM)
17.50%
Effective tax rate (TTM)
27.22%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
9.43%
Return on equity (TTM)
18.12%
Valuation
Price to earnings (TTM)
66.189
Price to revenue (TTM)
5.982
Price to book
10.7
Price to tangible book (TTM)
12.04
Price to free cash flow (TTM)
46.298
Free cash flow yield (TTM)
2.16%
Free cash flow per share (TTM)
4.974
Growth
Revenue change (TTM)
30.73%
Earnings per share change (TTM)
-39.85%
3-year revenue growth (CAGR)
27.54%
10-year revenue growth (CAGR)
26.22%
3-year earnings per share growth (CAGR)
274.37%
10-year earnings per share growth (CAGR)
10.39%
What the Analysts think about Insulet
Analyst ratings (Buy, Hold, Sell) for Insulet stock.
Insulet Financial Performance
Revenues and expenses
Insulet Earnings Performance
Company profitability
Insulet News
AllArticlesVideos
Securities Fraud Investigation Into Insulet Corporation (PODD) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Business Wire·2 days ago
Insulet Corporation (PODD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Business Wire·2 days ago
ATTENTION Insulet Corporation (PODD) Investors: Possible Fraud - Contact Levi & Korsinsky Today
Newsfile Corp·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insulet stock?
Insulet (PODD) has a market cap of $16B as of March 20, 2026.
What is the P/E ratio for Insulet stock?
The price to earnings (P/E) ratio for Insulet (PODD) stock is 66.19 as of March 20, 2026.
Does Insulet stock pay dividends?
No, Insulet (PODD) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next Insulet dividend payment date?
Insulet (PODD) stock does not pay dividends to its shareholders.
What is the beta indicator for Insulet?
Insulet (PODD) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.